Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esomeprazole is a proton pump inhibitor (PPI) used to reduce stomach acid production. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal and gastric ulcers, prevention of NSAID-associated gastric ulcers, eradication of *Helicobacter pylori* infection (in combination with antibiotics), and conditions involving excessive gastric acid such as Zollinger-Ellison syndrome. Esomeprazole works by specifically inhibiting the H+/K+-ATPase enzyme ("proton pump") in the gastric parietal cells, thereby blocking the final step in acid production. This inhibition is irreversible until new enzyme molecules are synthesized. The drug was developed by AstraZeneca.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esomeprazole.